PRECISION OPTICS CORPORATION, INC. 10-K

 true 2025 FY Amended to update Items 10 through 14 of Part III 0000867840

 0000867840

 2024-07-01
 2025-06-30

 0000867840

 2024-12-31

 0000867840

 2025-09-20

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 WASHINGTON, D.C. 20549

 FORM 10-K/A

 (Amendment No. 1)

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended June 30, 2025

 or

 TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from __________ to
__________

 Commission File Number 001-10647

 PRECISION OPTICS CORPORATION, INC.

 (Exact name of registrant as specified in its charter)

 Massachusetts

 04-2795294

 (State or Other
 Jurisdiction of

 (I.R.S. Employer

 Incorporation or Organization)

 Identification Number)

 22 East Broadway

 Gardner, Massachusetts 01440

 ( Address of principal executive offices) (Zip
Code)

 ( 978) 630-1800

 (Registrant's telephone number, including
area code)

 Securities registered pursuant to Section 12(b)
of the Act:

 Title of each class

 Trading symbol(s)

 Name of each exchange on which registered

 Common stock, $0.01 par value

 POCI

 Nasdaq Stock Market LLC

 Securities registered pursuant to Section 12(g)
of the Act: None

 Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes
 No

 Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
 No

 Indicate by check mark
whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes
 No

 Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by check mark whether
the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC 7262(b)) by the registered public accounting firm that
prepared or issued its audit report.

 If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Act. Yes No

 The aggregate market value
of the voting and non-voting common stock held by non-affiliates of the registrant on December 31, 2024 was approximately $ 23,911,000
based on a total of 4,960,885 shares of the registrant's common stock held by non-affiliates on such date, at the closing price
of $4.82 per share, as reported on Nasdaq on December 31, 2024.

 The number of shares of the registrant's common stock outstanding
as of September 20, 2025 was 7,714,701.

 Documents
incorporated by reference

 None

 Auditor
 Name:

 Auditor
 Location:

 Auditor
 Firm ID:

 STOWE
 & DEGON LLC

 Westborough,
 Massachusetts

 EXPLANATORY NOTE

 Precision Optics Corporation, Inc. is filing
this Amendment No. 1 on Form 10-K/A, or this Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended June 30, 2025,
or the Original 10-K, originally filed with the U.S. Securities and Exchange Commission, or SEC, on September 29, 2025, or Original Filing
Date, solely for the purpose of including the information required by Items 10 through 14 of Part III of Form 10-K. This information
was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in
the above-referenced items to be incorporated in the Original 10-K by reference from our definitive proxy statement so long as such proxy
statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment No. 1 to include the Part III information
in the Original Form 10-K because we will not file a definitive proxy statement containing such information within 120 days after the
end of the fiscal year covered by the Original 10-K.

 This Amendment No. 1 amends and restates in
their entirety Items 10 through 14 of the Original 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended,
or the Exchange Act, this Amendment No. 1 also contains new certifications by the principal executive officer and the principal financial
officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV is amended to include the currently
dated certifications of our principal executive officer and principal financial officer as exhibits. Because no financial statements
have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307
and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements
are included in this Amendment No. 1, new certifications of our principal executive officer and principal financial officer pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 1.

 Except as described above, no other changes
have been made to the Original 10-K. The Original 10-K continues to speak as of the date of the Original 10-K, and we have not updated
the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original 10-K.
Accordingly, this Amendment No. 1 should be read in conjunction with the Original 10-K. Defined terms used, but not defined, herein have
the meanings ascribed to them in the Original 10-K.

 Unless stated otherwise, references in this
Amendment No. 1 to "POCI," "Precision Optics," or "the Company", "we", "our"
and "us" are used herein to refer to Precision Optics Corporation, Inc.

 i

 PRECISION OPTICS CORPORATION, INC.

 FORM 10-K

 PAGE

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accounting Fees and Services

 Item 15.

 Exhibits, Financial Statement Schedules

 Signatures

 ii

 ITEM 10. DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 Directors and Executive Officers

 The following table sets forth the names and
ages of all of our directors and executive officers as of June 30, 2025. Our officers are appointed by, and serve at the pleasure of,
the Board of Directors.

 Name

 Age

 Position
 with our Company

 Joseph
 N. Forkey

 Chief
 Executive Officer, President, Treasurer and Director

 Wayne
 M. Coll

 Chief
 Financial Officer, Secretary

 Mahesh
 Lawande

 Chief
 Operating Officer

 Peter
 H. Woodward

 Chairman
 of the Board and Director

 Andrew
 J. Miclot

 Buell
 G. Duncan

 Joseph
 P. Pellegrino, Jr.

 Set
forth below is biographical information about each of the individuals named in the tables above:

 Joseph N. Forkey – Chief Executive
Officer, President, Treasurer and Director

 Dr. Joseph N. Forkey
has served as our Chief Executive Officer, President and Treasurer since February 8, 2011. Dr. Forkey has been a member of our Board
of Directors since 2006. He served as our Chairman of our Board of Directors from February 2011 to July 2014. He served as our Executive
Vice President and Chief Scientific Officer from April 2006 to February 2011 and held the position of our Chief Scientist from September
2003 to April 2006. Since joining us, he has been involved in general technical and management activities of our Company, as well as
investigations of opportunities that leverage our newly developed technologies. Dr. Forkey holds B.A. degrees in Mathematics and Physics
from Cornell University, and a Ph. D. in Mechanical and Aerospace Engineering from Princeton University. Prior to joining us, Dr. Forkey
spent seven years at the University of Pennsylvania Medical School as a postdoctoral fellow and research staff member. Dr. Forkey is
a valuable member of our Board due to his depth of scientific, operating, strategic, transactional, and senior management experience
in our industry. Additionally, Dr. Forkey has held positions of increasing responsibility at our Company and holds an intimate knowledge
of our Company due to his longevity in the industry and with us.

 Wayne M. Coll – Chief Financial
Officer, Secretary

 Mr. Coll was elected as Chief Financial Officer
and Secretary effective June 12, 2023. Mr. Coll has over 30 years of senior financial executive experience, primarily with medical device-based
businesses. He formerly served as Chief Financial Officer for Flowonix Medical Incorporated (July 2021- June 2023), Micron Products,
Inc. (July 2019 – July 2021), Keystone Dental, Inc. (September 2018 – May 2019), Modern Dental Laboratory USA, LLC (September
2013 – September 2018) and National Dentex Corporation (2007-2011). Mr. Coll received a B.S. in Business Administration and Accounting
from the University of Lowell, and an M.B.A. from the University of Massachusetts Lowell.

 Mahesh Lawande – Chief Operating
Officer

 Mr. Lawande
was elected as Chief Operating Officer on April 24, 2023. Mr. Lawande has senior operations and engineering experience primarily with
medical technology-based businesses. He formerly served as Senior Director of Supply Chain Operations in North America for Draeger Medical
Systems, Inc. (July 2017- June 2019), Director of Operations for Analogic Corporation (March 2021- March 2022), and Vice President –
Manufacturing and Operations for Third Pole Therapeutics (May 2022-April 2023). Mr. Lawande received a B.E. in Electronics and Communications
from Goa University, India, and an M.B.A. in Corporate Entrepreneurship and Strategy from F.W. Olin Graduate School of Business at Babson
College. On October 2, 2025, the Company and Mr. Mahesh Lawande mutually agreed to terminate his employment with the Company as of October
31, 2025, and Mr. Lawande transitioned to the roll of "Advisor to the President" for the period through October 31, 2025.

 Peter H. Woodward – Chairman of the Board

 Mr. Woodward was appointed
to our Board effective July 9, 2014 and as chairman of the Board in connection with the sale and purchase agreement we entered into in
July 2014. Mr. Woodward is the founder of MHW Capital Management, LLC, or MHW, a position he has held since September 2005. MHW specializes
in large equity investments in public companies implementing operating strategies to significantly improve their profitability. From
1996 to 2005, Mr. Woodward was the Managing Director for Regan Fund Management, LLC. He served as the President and Chief Executive Officer
and Director of Cartesian, Inc. from June 2015 to July 2018 and currently serves as Chairman of the Board and Chairman of the Audit Committee
for TSS, Inc., and as the CEO of Innovative Power, LLC. Mr. Woodward holds a BA in economics from Colgate University and a Masters of
International Affairs with a concentration in international economics and finance from Columbia University. He is also a Chartered Financial
Analyst.

 Andrew J. Miclot – Director

 Mr. Miclot was appointed to our Board on
March 2, 2016. Mr. Miclot has more than 35 years of leadership experience with medical device suppliers and brings substantial global
industry knowledge to our Company. From September 2020 to May 2021, Mr. Miclot was President of Electromedical Products International,
Inc., a medical device company treating anxiety, insomnia, depression and pain. Mr. Miclot was the President and Vice Chairman and Director
of WishBone Medical, Inc., a pediatric orthopedic company dedicated to the unmet needs of children suffering from orthopedic challenges
from October 2017 to January 2019. He has been on the Indiana University Alumni Association Advisory Board from October 2016 to October
2021. From October 2015 to January 2018, Mr. Miclot served as President, CEO and Director of Micro Machine Co., a supplier of medical
products for the orthopedic and spinal industries. Prior to joining Micro Machine Co., from May 2013 to September 2014, Mr. Miclot was
Executive Vice President of MicroTechnologies, Inc., a medical device supplier. Mr. Miclot was General Manager and Senior Vice President
of ArthroCare Corporation from June 2009 to March 2013. From January 2008 to March 2009, Mr. Miclot was President, CEO and Director of
Ascension Orthopedics, Inc. He was Vice President of Marketing for the orthopedic global business unit at Orthofix, Inc. from April 2007
to January 2008, and from March 1994 to April 2007, he served as Senior Vice President with Symmetry Medical Inc., a medical device supplier
and was also the Investor Relations Officer, after the NYSE IPO in December 2004 until April 2007. Mr. Miclot has a BA degree in Speech
and Hearing and an MA degree in Audiology from Indiana University and an MBA from the Lake Forest Graduate School of Management.

 Buell G. Duncan – Director

 On February 28, 2025, the Board appointed
Buell G. Duncan to fill the vacancy on the Board created with the retirement of Dr. Richard B. Miles. Since 2022, Mr. Duncan has served
as a Portfolio Advisor and Limited Partner for Iron Gate Capital, a venture capital firm focused on early-growth B2B technology companies,
a board observer of Share Mobility and Respondology, and a strategic advisor to Geminos AI, Demand Spring and Pillir Software. From 1992
through 2020, Mr. Duncan held various senior leadership positions at a number of IBM's global business units serving as Chief Marketing
Officer, IBM Cloud, Data and AI businesses from April 2017 until December 2020. Mr. Duncan brings decades of executive leadership and
strategic expertise, further strengthening the Company's commitment to innovation and growth.

 Joseph P. Pellegrino, Jr. –

 On March 19, 2025, the Board appointed Joseph
P. Pellegrino, Jr. to fill the vacancy created on the Board with the retirement of Peter Anania. From 2007 to his retirement on March
7, 2025, Mr. Pellegrino served as Chief Financial Officer of LeMaitre Vascular, Inc., a Nasdaq listed medical device company. He joined
LeMaitre Vascular as its Executive Vice President, Finance in 2005. Mr. Pellegrino served as a member of their Board of Directors beginning
in October 2016 until March, 2025. From 1997 to 2003, Mr. Pellegrino worked at Zoots, Inc., as Senior Vice President of Operations. Previously,
Mr. Pellegrino built and sold a regional mall-based specialty retailing company. Mr. Pellegrino has also served as an investment banking
analyst at Lehman Brothers, as part of their mergers and acquisitions group. Mr. Pellegrino received an A.B. in Economics from Harvard
College and an M.B.A. from the Harvard Business School. Mr. Pellegrino brings extensive operational and financial knowledge and experience
as Chief Financial Officer and Director of a publicly traded medical device company.

 No director is related to any other director
or executive officer of our company or our subsidiaries, and there are no arrangements or understandings between a director and any other
person pursuant to which such person was elected as director.

 GOVERNANCE OF THE COMPANY

 Board Leadership Structure

 Mr. Woodward has served
as our Chairman of our Board of Directors since July 9, 2014. Dr. Forkey has been our Chief Executive Officer, President and Treasurer
since February 8, 2011. Dr. Forkey manages the day-to-day affairs of our Company and leads the Board meetings. Mr. Woodward, Mr. Miclot,
who has served on our Board since March 2016 and Mr. Duncan and Mr. Pellegrino, who have recently joined our Board, are independent directors.
Our Board believes that having a majority of independent directors serves our Company well. The Board believes that its structure should
be informed by the needs and circumstances of our Company, the Board, and our shareholders. With this in mind, the Board believes that
its structure is currently serving our Company well and intends to maintain this as appropriate and practicable in the future.

 Risk Oversight of Management

 The Board of Directors
oversees management regarding our Company's risks. Our management keeps the Board of Directors apprised of significant risks facing
our Company and the approach being taken to understand, manage and mitigate such risks. Additional review or reporting on enterprise
risks is conducted as needed or as requested by the Board of Directors.

 Director Nominations

 The Board of Directors
nominates directors for election at each annual meeting of shareholders and appoints new directors to fill vacancies when they arise.
The Board is responsible for the identification, evaluation, and recruitment of qualified candidates to the Board of Directors for nomination
or election. It is the policy of the Company that the Board seek recommendations from the independent directors as to each person considered
for nomination or election as a director.

 One of the Board of Directors'
objectives in evaluating director nominations is to ensure that its membership is composed of experienced and dedicated individuals with
a diversity of backgrounds, perspectives and skills. The Board selects nominees for director based on the nominee's character, judgment,
diversity of experience, business acumen, and ability to act on behalf of all shareholders. We do not have a formal diversity policy;
however, the Board endeavors to have a Board representing diverse viewpoints as well as diverse expertise at policy-making levels in
many areas, including business, accounting and finance, manufacturing, marketing and sales, education, legal, government affairs, regulatory
affairs, research and development, business development, technology and in other areas that are relevant to our activities.

 The Board believes that
nominees for director should have experience, such as those mentioned above, that may be useful to our Company and the Board of Directors,
high personal and professional ethics and the willingness and ability to devote sufficient time to carry out effectively their duties
as directors. The Board believes it is appropriate for at least one, and, preferably, multiple, members of the Board of Directors to
meet the criteria for an "audit committee financial expert" as defined by rules of the SEC, and for a majority of the members
of the Board of Directors to meet the definition of "independent director" as defined by the Nasdaq Listing Rules. The Board
also believes it is appropriate for key members of our management to participate as members of the Board of Directors. Prior to each
annual meeting of shareholders, the Board identifies nominees first by evaluating the current directors whose term will expire at the
annual meeting and who are willing to continue in service. These candidates are evaluated based on the criteria described above, including
as demonstrated by the candidate's prior service as a director, and the needs of the Board of Directors with respect to the particular
talents and experience of its directors. In the event that a director does not wish to continue in service, the Board determines not
to re-nominate the director, a vacancy is created on the Board of Directors as a result of a resignation, an increase in the size of
the Board or other event, the Board will consider various candidates for Board membership, including those suggested by Board members,
officers, employees, customers, vendors, by an executive search firm engaged by the Board or by shareholders.

 The Board of Directors
will consider candidates for director positions that are recommended by any of our stockholders. Any such recommendation should be provided
to our Secretary. The recommended candidate should be submitted to us in writing addressed to our Secretary, c/o Precision Optics Corporation,
Inc., 22 East Broadway, Gardner, Massachusetts 01440. The recommendation should include the following information: name of candidate;
address, phone and fax number of candidate; a statement signed by the candidate certifying that the candidate wishes to be considered
for nomination to our Board of Directors and stating why the candidate believes that he or she would be a valuable addition to our Board
of Directors; a summary of the candidate's work experience for the prior five years and the number of shares of our stock beneficially
owned by the candidate.

 The Board will evaluate
the recommended candidate and shall determine whether or not to proceed with the candidate in accordance with our procedures. We reserve
the right to change our procedures at any time to comply with the requirements of applicable laws.

 Committees of the Board of Directors

 The Board of Directors has the responsibility
for establishing broad corporate policies and reviewing our overall performance rather than day-to-day operations. The Board's
primary responsibility is to oversee management of our Company and, in so doing, serve the best interests of our Company and our stockholders.

 Our Board of Directors has the ability to
establish, or disband, such committees as necessary or appropriate to serve the needs of our Company. The Board has designated an Audit
Committee and a Compensation Committee and has not established a nominating committee of the Board of Directors.

 Outside of the process provided by Rule 14a-8
of the Exchange Act, we do not have a formal policy concerning stockholder recommendations of candidates for board of director membership
and our bylaws do not provide for stockholders to submit proposals or director nominees for consideration at our annual meetings. Our
Board views that such a formal policy is not necessary at the present time given the Board of Directors willingness to consider candidates
recommended by Board members, officers, employees, customers, vendors, by an executive search firm engaged by the Board, or by stockholders.
Stockholders may recommend candidates by writing to our Secretary at our principal offices: c/o Precision Optics Corporation, Inc., 22
East Broadway, Gardner, Massachusetts 01440. The recommendation should include the following information: name of candidate; address,
phone and fax number of candidate; a statement signed by the candidate certifying that the candidate wishes to be considered for nomination
to our Board of Directors and stating why the candidate believes that he or she would be a valuable addition to our Board of Directors;
a summary of the candidate's work experience for the prior five years and the number of shares of our stock beneficially owned
by the candidate.

 Audit Committee and Audit Committee Financial Expert

 The Audit Committee of the Board of
Directors was established by the Board in July 2022 and is currently composed of Messrs. Woodward, Miclot and Pellegrino (Chair), who
was appointed on March 19, 2025. The Audit Committee acts on behalf of the Board, and its primary function is to oversee the financial
reporting and disclosure process. The Audit Committee has adopted a charter, which is available on the "Investor Relations"
portion of the Company's website located at

 The Board of Directors has made a
determination that Peter H. Woodward, Chairman of the Board and Member of the Audit Committee and Mr. Pellegrino (Chair of the Audit
Committee), each qualifies as an audit committee financial expert and meets the criteria set forth in Item 407(d)(5) of Regulation S-K.

 Each of Mr. Woodward, Mr. Miclot and Pellegrino
are "independent directors" as independence is currently defined in Rule 5605(d)(2) of the Nasdaq Stock Markets listing standards
and SEC Rule 10A-3 and each have an understanding of generally accepted accounting principles and financial statements and have the ability
to assess the general application of such principles in connection with the accounting for estimates, accruals and reserves, and has
an understanding of internal controls over financial reporting as well as audit committee functions. See Mr. Woodward's, Mr. Miclot's,
and Mr. Pellegrino's biography and qualifications described above.

 Compensation Committee

 The Compensation Committee of the Board of
Directors was established by the Board in May 2022 and is currently composed of Messrs. Woodward, Miclot (Chair) and Duncan. The Compensation
Committee has adopted a charter which is available on the Company's website.

 Under its charter, the Compensation
Committee of the Board acts on behalf of the Board to review and oversee the Company's overall compensation philosophy, and to
oversee the development and implementation of compensation programs aligned with the Company's business strategy. Specifically,
the Compensation Committee's authority includes reviewing and approving annually the corporate goals and objectives applicable
to the compensation of the chief executive officer, and to evaluate at least annually the CEO's performance in light of those
goals and objectives and determine and approve the CEO's compensation level based on that evaluation. In evaluating and determining
CEO compensation, the Committee considers the results of the most recent stockholder advisory vote on executive compensation ("Say
on Pay Vote") required by Section 14A of the Exchange Act. The CEO is not allowed to be present during any voting or deliberations
by the Committee on CEO compensation. Additionally, the Compensation Committee approves the compensation of all other executive officers,
in consultation with the CEO. In evaluating and determining executive compensation, the Committee considers the results of the most recent
Say on Pay Vote. The Compensation Committee also makes recommendations to the Board regarding the adoption of Stock Plans and equity-based
plans, which includes the ability to amend and terminate such plans. The Compensation Committee has the authority to administer the Company's
Stock Plans and equity-based plans, including designation of the employees to whom the awards are to be granted, the amount of the award
or equity to be granted and the terms and conditions applicable to each award or grant, subject to the provisions of each plan. The Compensation
Committee is responsible for overseeing the Company's submission to a stockholder vote of matters relating to compensation, including
advisory votes on executive compensation and the frequency of such votes, incentive and other compensation plans, and amendments to such
plans. The Compensation Committee is also responsible for performing any other activities required by applicable law, rules or regulations,
including the rules of the SEC and any exchange or market on which the Company's capital stock is traded, and performs other activities
that are consistent with the Compensation Committee's charter, the Company's certificate of incorporation and bylaws, and
governing laws, as the Compensation Committee or the Board deems necessary or appropriate.

 The charter of the Compensation Committee
grants the Compensation Committee full access to all books, records, facilities and personnel of the Company. In addition, under the
charter, the Compensation Committee has the discretion and authority to obtain, at Company expense, advice and assistance from compensation
consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee
considers necessary or appropriate in the performance of its duties.

 Shareholder Communications with the Board of Directors

 If you wish to communicate
with the Board of Directors, you may send your communication in writing to: Secretary, c/o Precision Optics Corporation, Inc., 22 East
Broadway, Gardner, Massachusetts, 01440. Please include your name and address in the written communication and indicate whether you are
a shareholder of Precision Optics. The Secretary will review any communication received from a shareholder, and all material communications
from shareholders will be forwarded to the appropriate director or directors or Committee of the Board of Directors based on the subject
matter.

 Delinquent Section
16(a) Reports

 Section 16(a) of the Securities Exchange Act
of 1934, as amended, requires our directors, executive officers and persons who own more than 10% of a registered class of our securities
to file reports of beneficial ownership and changes in beneficial ownership with the Securities and Exchange Commission on Forms 3 (Initial
Statement of Beneficial Ownership), 4 (Statement of Changes of Beneficial Ownership of Securities) and 5 (Annual Statement of Beneficial
Ownership of Securities). Officers, directors and greater than 10% beneficial owners are required by SEC regulations to furnish us with
copies of all Section 16(a) forms they file.

 Based solely upon a review of reports provided
to us by our officers and directors, we believe that, during the fiscal year ended June 30, 2024, no person required to file reports
under Section 16(a) of the Securities Exchange Act of 1934 failed to file such reports on a timely basis during such fiscal year except
for the following: Form 4s for Wayne M. Coll due on July 2, 2024, October 2, 2024 and January 3, 2025 related to the payment of shares
in lieu of cash per Mr. Coll's employment agreement, which was filed on February 11, 2025.

 Code of Ethics

 We have adopted a written code of ethics that
applies to our directors, principal executive officer, principal financial officer, principal accounting officer or controller and any
persons performing similar functions. The code of ethics has been filed as Exhibit 14.1 to our most recent Annual Report on Form 10-K.
We intend to disclose any future amendments to, or waivers from, the code of ethics within four business days of the waiver or amendment
through a website posting or by filing a Current Report on Form 8-K with the SEC.

 Insider Trading Policy

 Our Board has adopted an Insider Trading Policy
that applies to all of our directors, executive officers, and employees. The policy attempts to establish standards that will avoid even
the appearance of improper conduct on the part of insiders by requiring, among other things, that insiders maintain the confidentiality
of information about the Company and to not engage in transactions in the Company's securities while aware of material nonpublic
information.

 ITEM 11. EXECUTIVE
COMPENSATION.

 Named Executive Officers

 This
Annual Report contains information about the compensation paid to our Named Executive Officers, as defined by Item 402(m)(2) of Regulation
S-K, during our fiscal year ending June 30, 2025. In accordance with the rules and regulations of the Securities and Exchange Commission
for smaller reporting companies, we determined that the following officers were our Named Executive Officers:

 •

 Joseph N. Forkey, Chief
 Executive Officer, President, Treasurer and Director;

 •

 Wayne M. Coll, Chief Financial Officer; and

 •

 Mahesh Lawande, Chief Operating Officer.

 Compensation Overview

 We qualify as a "smaller
reporting company" under the rules promulgated by the Securities and Exchange Commission, and we have elected to comply with the
disclosure requirements applicable to smaller reporting companies. Accordingly, this executive compensation summary is not intended to
meet the "Compensation Discussion and Analysis" disclosure required of larger reporting companies.

 Role of the Board

 The Board of Directors
has authorized the Compensation Committee to oversee and determine executive compensation, and review our major compensation plans, policies,
and programs. All compensation for our Chief Executive Officer and our Chief Financial Officer is determined by the Compensation Committee.
The Compensation Committee is charged with the responsibility of reviewing the performance and establishing the total compensation of
our Chief Executive Officer and our Chief Financial Officer on an annual basis. The Compensation Committee often discusses compensation
matters with the Board as part of our regularly scheduled Board meetings. The Compensation Committee administers our incentive plans
and is responsible for approving grants of equity awards under such plans. We believe that our Compensation Committee adequately fulfilled
its role in overseeing our compensation policies in the past.

 Compensation Philosophy and Objectives

 Due to the size of our
Company, the performance of our Chief Executive Officer, our Chief Financial Officer and our Chief Operating Officer directly affects
all aspects of our results. Consequently, our compensation philosophy is to reward these executive officers for the achievement of short-
and long-term corporate and individual performance, as measured by the attainment of specific goals for the creation of long-term shareholder
value. Also, to ensure that we are strategically and competitively positioned for the future, the Board has the discretion to attribute
significant weight to other factors in determining executive compensation, such as maintaining competitiveness, expanding markets, pursuing
growth opportunities and achieving other long-range business and operating objectives. The level of compensation should also allow us
to attract, motivate, and retain talented executive officers that contribute to our long-term success. The compensation of our Chief
Executive Officer, Chief Financial Officer and Chief Operating Officer is comprised of cash compensation and long-term incentive compensation
in the form of base salary, restricted stock and stock options with the possibility to earn bonuses.

 Summary Compensation Table for the Years Ended June
30, 2025 and 2024

 The following table sets
forth all compensation for our fiscal years ended June 30, 2025 and 2024 awarded to, earned by, or paid to our Principal Executive Officer,
our most highly compensated executive officer and our most highly compensated employee, all of which are referred to herein as the "Named
Executive Officers." No other executive officer earned over $100,000 in the last completed fiscal year.

 Name and Principal Position

 Year
 June 30,

 Salary
 ($)

 Bonus
 ($)

 Option
 Awards
 ($) (1)

 Total
 ($)

 Dr. Joseph N. Forkey

 2025

 270,359

 94,200
 (2)

 742.000
 (3)

 1,106,559

 Director, Chief Executive Officer, President and Treasurer

 2024

 251,032

 251,032

 Wayne M. Coll

 2025

 301,584

 185,500
 (4)

 487,084

 Chief Financial Officer, Secretary

 2024

 301,523

 301,523

 Mahesh Lawande

 2025

 275,552

 148,400
 (5)

 423,952

 Chief Operating Officer

 2024

 275,552

 275,552

 (1)

 Represents
 the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB
 ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant
 using the Black-Scholes option valuation model. A discussion of the assumptions used in calculating the amounts in this column may
 be found in the Notes to our audited consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended
 June 30, 2025. These amounts do not represent the actual amounts paid to or realized by the executives during the fiscal years presented.

 (2)

 We issued Dr. Forkey
 20,000 shares of our common stock on March 19, 2025 with a fair market value based on the closing price of our common stock of $4.71
 per share on that date, or $94,200, as a performance bonus.

 (3)

 We granted Dr. Forkey
 a stock option to purchase up to 200,000 shares of our common stock at an exercise price of $4.71 per share, the closing price of
 our common stock on March 19, 2025. 80,000 options vest on the grant date and the remaining 120,000 options vest in three increments
 three pro rata increments on March 19, 2026, 2027, and 2028.

 (4)

 We granted Mr. Coll
 a stock option to purchase up to 50,000 shares of our common stock at an exercise price of $4.71 per share, the closing price of
 our common stock on March 19, 2025. These options vest in two pro rata increments on March 19, 2026 and 2027.

 (5)

 We
 granted Mr. Lawande a stock option to purchase up to 40,000 shares of our common stock at an exercise price of $4.71 per
 share, the closing price of our common stock on March 19, 2025. These options vest in two pro rata increments on March 19,
 2026 and 2027. As Mr. Lawande's last day of employment with the Company will be October 31, 2025, the option to purchase
up of 40,000 shares will not vest and will be forfeited

 Narrative
to Summary Compensation Table

 Named Executive Officer Employment Agreements

 Agreement with Dr. Forkey

 On July 27, 2018, our Board of Directors approved
a new compensation agreement with our Chief Executive Officer, Dr. Joseph Forkey, effective August 2, 2018. Pursuant to the agreement,
we agreed to pay Dr. Forkey a base salary of $200,000 per year beginning retroactively on July 1, 2018. Effective October 1, 2019, our
Board of Directors approved an increase of Dr. Forkey's base salary to $250,000 per year and effective March 20, 2025, our Board
of Directors approved an increase of Dr. Forkey's base salary to $325,000 per year.

 Agreement with Mr. Coll

 As of June 12, 2023, we entered into an Employment
Agreement with Wayne M. Coll to serve as our Chief Financial Officer and Secretary, pursuant to which we agreed to pay Mr. Coll a base
salary of $300,000 per year. We also granted Mr. Coll a stock option to purchase up to 50,000 shares of common stock at $6.94 per share,
with annual vesting in three equal increments beginning June 12, 2024.

 Agreement with Mr. Lawande

 As of April 24, 2023, we entered into an Employment
Agreement with Mahesh Lawande to serve as our Chief Operating Officer, pursuant to which we agreed to pay Mr. Lawande a base salary of
$275,000 per year. We also granted Mr. Lawande a stock option to purchase up to 60,000 shares of common stock at $6.40 per share, with
annual vesting in three equal increments beginning April 24, 2024.

 Outstanding Equity Awards at Fiscal Year-End
Table for the Fiscal Year Ended June 30, 2025

 The following table shows grants of options
outstanding on June 30, 2025, the last day of our most recent fiscal year, to each of the Named Executive Officers included in the Summary
Executive Compensation Table.

 Name

 Number
 of securities
 underlying unexercised options
 Exercisable

 Number
 of securities
 underlying unexercised options Unexercisable

 Option
 exercise
 price ($)

 Option
 expiration
 date

 Dr. Joseph N. Forkey

 116,666

 2.19

 08/02/2028

 50,000

 5.04

 06/04/2031

 80,000

 120,000
 (1)

 4.71

 3/19/2035

 Wayne M. Coll

 33,333

 16,667

 6.94

 6/12/2033

 50,000
 (2)

 4.71

 3/19/2035

 Mahesh Lawande

 40,000

 20,000

 6.40

 4/24/2033

 40,000
 (3)

 4.71

 3/19/2035

 (1)

 We granted Dr. Forkey a stock option to purchase up to 200,000 shares of our common
 stock at an exercise price of $4.71 per share, the closing price of our common stock on March 19, 2025, with 80,000 shares vesting
 on the grant date and the remaining 120,000 shares with annual vesting in three equal annual increments beginning March 19, 2026.

 (2)

 We granted Mr. Coll a stock option to purchase up to 50,000 shares of our common stock at an exercise
 price of $4.71 per share, the closing price of our common stock on March 19, 2025. These options vest in two pro rata increments
 on March 19, 2026, and 2027.

 (3)

 We granted Mr. Lawande a stock option to purchase up to 40,000 shares of our common stock at an
 exercise price of $4.71 per share, the closing price of our common stock on March 19, 2025. These options vest in two pro rata increments
 on March 19, 2026, and 2027.

 Profit
 Sharing and 401(k) Plan

 We have a defined contribution 401(k) profit
sharing plan. Employer profit sharing and matching contributions to the plan are discretionary. No employer profit sharing contributions
were made to the plan in fiscal years 2025 and 2024. No employer matching contributions were made to the plan in fiscal years 2025 and
2024.

 Director Compensation

 The following table sets
forth cash amounts and the value of other compensation paid to our directors for the fiscal year ended June 30, 2025, but does not include
the compensation of Dr. Joseph N. Forkey, our Chief Executive Officer, President, and Treasurer, as his compensation is reflected in
the Summary Executive Compensation Table.

 Name of Director

 Fees earned or paid in cash

 ($)(1)

 Option awards
($)(2)

 Total
 ($)

 Andrew J. Miclot

 27,500

 98,242

 125,742

 Richard B. Miles (3)

 5,000

 39,846

 44,846

 Peter V. Anania (4)

 5,000

 39,846

 44,846

 Peter H. Woodward

 40,000

 119,538

 159,538

 Buell G. Duncan (5)

 12,500

 166,950

 179,450

 Joseph J. Pellegrino, Jr. (6)

 15,000

 166,950

 181,950

 _______________________

 (1)

 Under our director compensation plan, each non-management, non-Chairman board
member shall receive $20,000, committee members receive an additional $5,000. and committee chairs receive an additional $5,000 Mr. Woodward
serves as our Chairman and receives $10,000 per quarter. We also reimburse our directors for travel expenses.

 (2)

 On November 18, 2024,
 options to purchase up to 10,000 shares of common stock were granted to Mr. Miclot, Dr. Miles, and Mr. Anania, and up to 30,000 shares
 to Mr. Woodward, at an exercise price of $4.71 per share.

 (3)

 On February 28, 2025,
 Dr. Miles resigned from the Board of Directors.

 (4)

 On March 14, 2025, Mr.
 Anania resigned from the Board of Directors.

 (5)

 Mr. Duncan joined the
 Board in February 2025. On March 19, 2025, the Board awarded the following stock options to Mr. Duncan: (i) a stock option to purchase
 30,000 shares of Common Stock at an exercise price of $4.71, with all of the underlying shares vested as of the date of grant, as
 a one-time grant for joining the Board of Directors and (ii) a stock option to purchase 15,000 shares of Common Stock at an exercise
 price of $4.71, with 7,500 of the underlying shares vesting on June 29, 2025 and 7,500 shares vesting on September 29, 2025, for
 services during April – September of 2025.

 (6)

 Mr. Pellegrino joined
 the Board in March 2025. On March 19, 2025, the Board awarded the following stock options to Mr. Pellegrino: (i) a stock option to
 purchase 30,000 shares of Common Stock at an exercise price of $4.71, with all of the underlying shares vested as of the date of
 grant, as a one-time grant for joining the Board of Directors and (ii) a stock option to purchase 15,000 shares of Common Stock at
 an exercise price of $4.71, with 7,500 of the underlying shares vesting on June 29, 2025 and 7,500 shares vesting on September 29,
 2025, for services during April – September of 2025.

 As of June 30, 2025, the following outstanding
stock options were held by each of the individuals listed above: Andrew J. Miclot – 114,998, Dr. Richard B. Miles – 90,998,
Peter V. Anania –66,666, Peter H. Woodward – 135,000, Buell G. Duncan – 45,000 and Joseph J. Pellegrino, Jr –
45,000.

 Narrative to Director Compensation Table

 Under our Non-Employee Director Compensation
Plan in effect during fiscal 2024, each non-management, non-Chairman board member shall receive $10,000 annually paid in quarterly amounts
of $2,500. Each non-management, non-Chairman board member who chairs a committee was paid an additional $10,000 annually paid in quarterly
amounts of $2,500. In accordance with a separate agreement, the Chairman of the Board, Mr. Woodward, receives $10,000 per quarter for
the greater time commitment required to perform the duties of Chairman of the Board. We also reimburse our directors for travel expenses.

 Under our Non-Employee Director Compensation
Plan in effect during fiscal 2025, each non-employee director will receive an annual cash award of $20,000, Committee members will receive
an additional cash award of $5,000, Committee chairs will receive an additional cash award of $5,000 and the Chairman of the Board will
receive an additional cash award of $10,000, all payable quarterly in arrears, and an annual stock option grant of 30,000 shares to be
granted on the second business day following the filing of the Company's 10-Q reporting the Company's first fiscal quarter
results with 1/4 of the underlying shares vesting each quarter following the date of such grant.

 Granting of Certain Equity Awards Close
in Time to the Release of Material Nonpublic Information

 We do not grant equity awards in anticipation
of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time
the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to
any named executive officer during the period beginning four business days before and ending one business day after the filing of a period
report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of
material nonpublic information for the purpose of affecting the value of executive compensation.

 Recoupment Policy

 We adopted the Precision Optics Corporation,
Inc. Clawback Policy effective as of October 2, 2023. In the event we are required to prepare an accounting restatement of our financial
statements due to our material noncompliance with any financial reporting requirement under the securities laws, the Board will require
reimbursement or forfeiture of any excess incentive compensation received by any covered executive during the three completed fiscal
years immediately preceding the date on which we are required to prepare an accounting restatement. "Clawback" or recoupment
policy in our executive compensation program contributes to creating and maintaining a culture that emphasizes integrity and accountability
and reinforces the performance-based principles underlying our executive compensation program.

 ITEM 12. SECURITY OWNERSHIP
OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 The following table sets forth information, as of June 30, 2025,
regarding beneficial ownership of our common stock by:

 •

 each
 of our directors;

 •

 each
 of our named executive officers;

 •

 all
 directors and executive officers as a group; and

 •

 each
 person, or group of affiliated persons, known by us to beneficially own more than five percent of our shares of common stock.

 Beneficial ownership is determined according
to the rules of the SEC, and generally means that person has beneficial ownership of a security if he or she possesses sole or shared
voting or investment power of that security and includes options that are currently exercisable or exercisable within 60 days. Each director
or officer, as the case may be, has furnished us with information with respect to beneficial ownership. Except as otherwise indicated,
we believe that the beneficial owners of common stock listed below, based on the information each of them has given to us, have sole
investment and voting power with respect to their shares, except where community property laws may apply. Except as otherwise noted below,
the address for each person or entity listed in the table is c/o Precision Optics Corporation, Inc., 5300 Memorial Drive, Suite 950,
Houston, Texas 77007.

 Amount
 of beneficial ownership (1)

 Percent
 of

 Name
 and Address of Beneficial Owner

 Owned

 –

 Rights to

 Acquire

 Total

 Number

 Beneficially

 Owned (2)

 Dolphin Offshore Partners LP
 (3)

 4828 First Coast Highway, STE 5

 Fernandina, FL 32034

 561,712

 561,712

 7.28%

 Sandra F., Norman H. and Brian L. Pessin (4)

 400 E.51 st Street PH 31

 New York, NY 10022

 1,110,056

 1,110,056

 14.39%

 MHW Partners, L.P. (5)

 Attn: Peter Woodward

 Jennifer Court

 Narragansett, RI 02882

 358,099

 127,500

 485,599

 6.29%

 Needham Asset Management L.L.C. (6)

 250 Park Avenue, 10 th Floor

 New York, New York 10117

 700,000

 700,000

 9.07%

 (1)

 Represents
 shares with respect to which each beneficial owner listed has or will have, upon acquisition of such shares upon exercise or conversion
 of options, warrants, conversion privileges or other rights exercisable within 60 sixty days, sole voting and investment power. For
 the purposes of this table, we have not assumed the limitations on exercise set forth in certain options, which limit the number
 of shares of common stock that the holder, together with all other shares of common stock beneficially owned by such person, does
 not exceed 4.999% of the total outstanding shares of common stock.

 (2)

 As of June 30, 2025,
 there were 7,714,701 issued shares of our common stock issued and outstanding. Percentages are calculated on the basis of the amount
 of issued and outstanding common stock plus, for each person or group, any securities that such person or group has the right to
 acquire within 60 days of June 30, 2025 pursuant to options, warrants, conversion privileges or other rights.

 (3)

 We relied, in part,
 on the Schedule 13D/A filed jointly by Dolphin Offshore Partners, L.P., Dolphin Mgmt. Services, Inc. and Peter E. Salas on March
 20, 2023 for this information.

 Dolphin
 Offshore Partners, L.P., a Delaware limited partnership, is an investment manager. Dolphin Mgmt. Services, Inc., a Delaware corporation,
 is the managing general partner of Dolphin Offshore Partners, L.P. Peter E. Salas is the President, sole shareholder and controlling
 person of Dolphin Mgmt. Services, Inc. Peter Salas is a U.S. citizen.

 Dolphin Offshore Partners,
 L.P., Dolphin Mgmt. Services, Inc. and Peter E. Salas each may be deemed to beneficially own an aggregate of 561,712 shares of common
 stock. Dolphin Offshore Partners, L.P., Dolphin Mgmt. Services, Inc. and Peter E. Salas each may be deemed to have shared voting
 power and shared dispositive power, of all such shares of common stock.

 (4)

 We relied, in part,
 on a Schedule 13D/A filed jointly with the SEC on February 24, 2025 by Sandra F. Pessin, Brian L. Pessin and Norman H. Pessin. Mr.
 Norman H. Pessin and Mrs. Sandra F. Pessin are married and considered to beneficially hold each other's shares. Ms. Sandra
 F. Pessin owns 477,361 shares, for which she has sole voting and dispositive power, Mr. Norman Pessin owns 151,4663 shares, for which
 he has sole voting and dispositive power, and Mr. Brian Pessin owns 481,229 shares, for which he had sole voting and dispositive
 power, for a combined beneficial ownership of 1,110,056 shares. Norman and Sandra Pessin are the parents of Brian Pessin.

 (5)

 We relied, in part,
 on a Form 4 filed with the SEC on February 25, 2025 by Mr. Woodward, and on a Schedule 13D/A jointly filed with the SEC on November
 3, 2015 by MHW Partners, L.P., MHW Capital, LLC, MHW Capital Management, LLC for this information.

 MHW Partners, L.P. is
 a Delaware limited partnership. MHW Capital, LLC is a Delaware limited liability company. MHW Capital Management, LLC is a Delaware
 limited liability company. MHW Capital, LLC is the general partner of MHW Partners, L.P. Mr. Woodward is the principal of MHW Capital
 Management, LLC and MHW Capital, LLC and in such capacity, Mr. Woodward holds the power to vote and direct the disposition of all
 shares of common stock owned by MHW Partners, L.P. Mr. Woodward is a citizen of the United States and our current Chairman of our
 Board of Directors.

 MHW Partners, L.P. beneficially
 owns 327,171 shares of common stock. Mr. Woodward owns 15,464 shares and holds 135,000 shares that may be acquired upon the exercise
 of outstanding stock options, of which 127,500 have vested with 7,500 shares vesting on September 29, 2025 for services during April
 – September of 2025.

 (6)

 We relied, in part,
 on a Schedule 13G filed with the SEC on May 14, 2025 by Needham Investment Management L.L.C., Needham Asset Management, LLC, Needham
 Aggressive Growth Fund and George A. Needham for this information.

 Needham Investment Management
 L.L.C., Needham Asset Management, LLC, Needham Aggressive Growth Fund and George A. Needham in the aggregate beneficially own 700,000
 shares of common stock and share the power to vote and direct the disposition of all shares.

 Officers and Directors

 Amount of beneficial ownership
 (2)

 Percent of

 Name and address of beneficial owner (1)

 Nature of beneficial ownership

 Owned

 Shares – Rights
 to Acquire

 Total
 Number

 Beneficially
 Owned
 (3)

 Dr. Joseph N. Forkey (4)

 Chief Executive Officer, President, Treasurer and Director

 142,572

 246,666

 389,238

 4.89
 %

 Peter H. Woodward (5)

 Chairman of the Board of Directors

 342,635

 127,500

 470,135

 6.09
 %

 Buell G. Duncan (6)

 30,000

 30,000

 *

 Andrew J. Miclot (7)

 99,998

 99,998

 1.28
 %

 Joseph Pellegrino (8)

 30,000

 30,000

 *

 Wayne M. Coll (9)

 Chief Financial Officer, Secretary

 8,878

 16,666

 25,544

 *

 Mahesh Lawande (10)

 Chief Operating Officer

 1,726

 40,000

 41,726

 *

 All directors and executive officers as a group

 480,347

 614,997

 1,095,344

 13.92
 %

 * Percentage of shares beneficially owned
does not exceed one percent of issued and outstanding shares of stock.

 _______________________

 (1)

 Unless otherwise
 stated, the address of each beneficial owners listed on the table is c/o Precision Optics Corporation, Inc., 22 East Broadway, Gardner,
 MA 01440.

 (2)

 Represents shares with
 respect to which each beneficial owner listed has or will have, upon acquisition of such shares upon exercise or conversion of options,
 warrants, conversion privileges or other rights exercisable within 60 sixty days, sole voting and investment power.

 (3)

 As of June 30, 2025,
 there were 7,714,701 shares of our common stock issued and outstanding. Percentages are calculated on the basis of the amount of
 issued and outstanding common stock plus, for each person or group, any securities that such person or group has the right to acquire
 within 60 days of June 30, 2025 pursuant to options, warrants, conversion privileges or other rights.

 (4)

 Dr. Forkey
 is a member of our Board of Directors and serves as our Chief Executive Officer, President and Treasurer. Dr. Forkey's beneficial
 ownership consists of (a) 142,572 shares of common stock, and (b) 246,666 shares of common stock that may be acquired upon the exercise
 of outstanding stock options. On March 19, 2025, Dr. Forkey was granted 200,000 options,with 80,000 shares vesting on the grant
 date and the remaining 120,000 shares with annual vesting in three equal installments on March 19, 2026, March 19, 2027, and March
 19, 2028, subject to his remaining in the continuous employment of the Company through such applicable date.

 (5)

 Mr. Peter Woodward is
 the Chairman of our Board of Directors. Mr. Woodward's beneficial ownership consists of (a) 327,171 shares of common stock
 held through MHW Partners, L.P., (b) 15,464 shares held by Mr. Woodward and (c) options to purchase 127,500 shares exercisable within
 sixty days of June 30, 2025. Mr. Woodward also owns options to purchase 7,500 shares vesting on September 29, 2025 for services
 during July – September of 2025.

 (6)

 Mr. Duncan was appointed
 to the Board on February 28, 2025, and did not own any shares in the Company as of his appointment. On March 19, Mr. Duncan was awarded
 a stock option to purchase 30,000 shares of Common Stock at an exercise price of $4.71, with all of the underlying shares vested
 as of the date of grant, as a one-time grant for joining the Board of Directors and (ii) a stock option to purchase 15,000 shares
 of Common Stock at an exercise price of $4.71, with 7,500 of the underlying shares vesting on on September 29, 2025, for services
 during July – September of 2025.

 (7)

 Mr. Miclot is a member
 of our Board of Directors. Mr. Miclot's beneficial ownership consists of 99,998 shares of common stock that may be acquired
 upon the exercise of outstanding stock options within sixty days of June 30, 2025. Mr. Miclot also has options to purchase 7,500
 shares vesting on September 29, 2025 for services during July – September of 2025.

 (8)

 Mr. Pellegrino was appointed
 to the Board on March 19, 2025, and did not own any shares in the Company as of his appointment. On March 19, 2025, Mr. Duncan was
 awarded a stock option to purchase 30,000 shares of Common Stock at an exercise price of $4.71, with all of the underlying shares
 vested as of the date of grant, as a one-time grant for joining the Board of Directors and (ii) a stock option to purchase 15,000
 shares of Common Stock at an exercise price of $4.71, with 7,500 of the underlying shares vesting on September 29, 2025, for services
 during July – September of 2025.

 (9)

 Mr. Coll is our Chief
 Financial Officer and Secretary effective June 12, 2023. Mr. Coll's beneficial ownership consists of (a) 8,878 shares of common
 stock and (b) 33,333 shares of common stock that may be acquired upon the exercise of outstanding stock options within sixty days
 of June 30, 2025. Mr. Coll also owns options to purchase 16,667 shares vesting on June 12, 2026, 25,000 shares vesting
 on March 19, 2026 and 25,000 shares vesting on March 19, 2027.

 (10)

 Mr. Lawande is our Chief
 Operating Officer effective April 24, 2023. Mr. Lawande's beneficial ownership consists of (a) 1,726 shares of common stock
 and (b) 40,000 shares of common stock that may be acquired upon the exercise of outstanding stock options within sixty days of June
 30, 2025. Mr. Lawande also owns option to purchase 20,000 shares vesting on April 24, 2026, 20,000 shares vesting on March 19, 2026
 and 20,000 shares vesting on March 19, 2027. As Mr. Lawande's last day of employment with the Company will be October 31, 2025, the option to purchase
up of 40,000 shares will not vest and will be forfeited

 As of June 30, 2024 and June 30, 2025, there
were no arrangements among our beneficial owners, known to management, which may result in a change in control of our Company.

 Securities Authorized for Issuance under
Equity Compensation Plans

 The following table sets forth information
regarding our equity compensation plans at June 30, 2025:

 Plan Category

 Number of securities to be issued
 upon exercise of outstanding options, warrants and rights (a)

 Weighted-average exercise price
 of outstanding options, warrants and rights (b)

 Number of securities remaining available
 for future issuance under equity compensation plans (excluding securities reflected in column (a))

 Equity compensation plans approved by security holders

 876,091

 5.46

 57,242

 Equity compensation plans not approved by security holders (1)

 747,485

 4.13

 –

 Total

 1,623,576

 4.85

 57,242

 (1) Consists of stock
options issued under the 2021 Equity Incentive Plan, as further described below.

 2021 Equity Incentive Plan

 The Precision Optics Corporation, Inc. 2021
Equity Incentive Plan, referred to as the 2021 Plan, was adopted by our Board of Directors on May 10, 2021. The 2021 Plan allows for
the granting of stock options and other equity incentive instruments to selected employees, directors and other persons who provide services
to us or our affiliates for up to a total of 1,000,000 shares of the Company's common stock. In connection therewith, we filed
a registration statement on Form S-8 to register the 1,000,000 shares of common stock. Grants may no longer be issued under this plan.

 2022 Equity Incentive Plan

 The Precision Optics Corporation,
Inc. 2022 Equity Incentive Plan, referred to as the 2022 Plan, was adopted by our Board of Directors on February 10, 2022, and approved
by our stockholders on April 8, 2022. The 2022 Plan allows for the granting of stock options and other equity incentive instruments to
selected employees, directors and other persons who provide services to us or our affiliates for up to a total of 333,333 shares of the
Company's common stock, which total may be increased annually without a further vote of stockholders in an amount determined by
our Board of directors, but not to exceed 5% of the number of outstanding shares of common stock on the last day of the immediately preceding
year. As permitted by the Plan, the Board of Directors on September 20, 2023, February 7, 2025 and again on August 12, 2025, approved
an amendment increasing the number of shares that may be issued under the 2022 Plan by 300,000 shares, 300,000 shares and 385,000 shares,
in each instance. In connection therewith, we filed a registration statement on Form S-8 covering 633,333 shares of Common Stock issuable
under the 2022 Plan on October 26, 2023, and a registration statement on Form S-8 covering 300,000 shares of Common Stock issuable under
the 2022 Plan on March 19, 2025. We expect to file an additional registration statement on Form S-8 covering the 385,000 shares of Common
Stock recently approved by the Board under the 2022 Plan.

 ITEM 13. CERTAIN RELATIONSHIPS
AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 Policies and Procedures for Related Party
Transactions

 It is our policy that
all employees, officers and directors must avoid any activity that is or has the appearance of conflicting with the interests of our
Company. Our Board reviews all related party transactions for potential conflict of interest situations on an ongoing basis and all such
transactions relating to executive officers and directors must be approved by the Board. In carrying out this responsibility, the Board
has determined that we do not have any related party transactions.

 Director Independence

 The rules of the Nasdaq Stock Market, or the
Nasdaq Rules, require a majority of a listed company's board of directors to be composed of independent directors. In addition,
the Nasdaq Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating
and governance committees be independent. Under the Nasdaq Rules, a director will only qualify as an independent director if, in the
opinion of our Board of Directors, that person does not have a relationship that would interfere with the exercise of independent judgment
in carrying out the responsibilities of a director. The Nasdaq Rules also require that audit committee members satisfy independence criteria
set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. In order to be considered independent
for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member
of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory,
or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company
or any of its subsidiaries. In considering the independence of compensation committee members, the Nasdaq Rules require that our board
of directors must consider additional factors relevant to the duties of a compensation committee member, including the source of any
compensation we pay to the director and any affiliations with our company.

 Our board of directors undertook a review
of the composition of our board of directors and its committees and the independence of each director. Based upon information requested
from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our
board of directors has determined that Messrs. Woodward, Duncan, and Pellegrino are independent as defined under the Nasdaq Rules.

 ITEM 14. PRINCIPAL
ACCOUNTING FEES AND SERVICES.

 Stowe & Degon LLC
has audited our financial statements since 2008. The aggregate fees billed to us for professional accounting services, including the
audit of our annual consolidated financial statements by our independent registered public accounting firm for the years ended June 30,
2025 and 2024, are set forth in the table below.

 Year Ended June 30,

 2025

 2024

 Audit fees

 $
 158,096

 $
 144,090

 Audit Related Fees

 –

 –

 Tax fees

 11,900

 11,500

 Other fees

 3,850

 10,430

 Total fees

 $
 173,746

 $
 166,020

 For purposes of the preceding table, the professional fees are
classified as follows:

 Audit Fees. Audit fees for fiscal year
2025 are comprised of fees for professional services performed for the audit of our annual financial statements and review of our quarterly
financial statements of $151,500 including direct out-of-pocket expenses in the amount of $6,496. Audit fees for fiscal year 2024 are
comprised of fees for professional services performed for the audit of our annual financial statements and review of our quarterly financial
statements of $140,000 including direct out-of-pocket expenses in the amount of $4,090.

 Audit-related Fees. Audit-related fees
are comprised of fees for assurance and related attestation services that are reasonably related to the performance of the audit of our
annual financial statements, or the review thereof, and fees for due diligence services.

 Tax Fees: Tax fees for fiscal 2025
and 2024 are comprised of fees for professional services performed with respect to corporate tax compliance, tax return preparation and
filing, tax planning and tax advice.

 Audit Committee Pre-Approval Policies
and Procedures

 In consultation with
our Chief Financial Officer, the Audit Committee pre-approves all services provided by our independent registered public accounting firm.
100% of the above services and fees were reviewed and approved by the Board of Directors either before or after the respective services
were rendered. The Board of Directors has considered the nature and amount of fees billed by Stowe & Degon LLC and believes that
the provision of services for activities unrelated to the audit is compatible with maintaining the firm's independence.

 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

 (a)

 Documents filed as part
 of this Annual Report.

 (1)

 Financial
 Statements. See Index to the Consolidated Financial Statements, which appear on the Original 10-K. The consolidated financial statements
 listed in the accompanying Index to the Consolidated Financial Statements are filed therewith in response to this Item.

 (2)

 Financial Statements
 Schedules. All schedules are omitted because they are not applicable or because the required information is contained in the financial
 statements or notes included in this report.

 (b)

 The exhibits listed
 in Part IV, Item 15(b) of the Original 10-K and the exhibits listed below are filed with, or incorporated by reference into, this
 report.

 Exhibit

 Description

 31.3

 Certification
 of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 31.4

 Certification
 of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 101.INS*

 101.SCH*

 Schema Document

 101.CAL*

 Calculation Linkbase Document

 101.DEF*

 Definition Linkbase Document

 101.LAB*

 Label Linkbase Document

 101.PRE*

 Presentation Linkbase Document

 104*

 Cover Page Interactive

 SIGNATURES

 Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.

 PRECISION OPTICS CORPORATION, INC.

 By:

 /s/ Wayne M. Coll

 Wayne M. Coll

 Chief Financial Officer (Principal Financial and Accounting
Officer)

 Date: October 28, 2025